Tumor Volume on Biopsy in Low-Risk Prostate Cancers Managed on Active Surveillance

Contemporary clinical guidelines recommend use of active surveillance (AS) in men with low-risk prostate cancer. Low-risk disease spans any potential volume of Gleason score 6 cancer without sufficient attention to tumor volume in the past. We therefore compared tumor characteristics in low-risk men managed on AS to men undergoing RP.

We evaluated an institutional cohort of 1633 men with very low-risk (clinical stage=T1c, PSA density<0.15, ≤2 positive cores, ≤50% core involvement) and low-risk disease (clinical stage≤T2a, PSA<10ng/ml, and Gleason score≤6). Among low-risk patients, we calculated the proportion failing to meet very low-risk volume criteria (>2 positive cores or >50% core involvement). Clinical and pathological metrics in the AS cohort were compared to a cohort of low-risk men undergoing radical prostatectomy (RP) in the current era (2011-2016).

Among the AS cohort, 1119 men (69%) met very low-risk criteria and 514 (31%) had low-risk disease. Of the low-risk population, only 138 men (27%) harbored higher-volume cancer exceeding very low-risk criteria as compared to 815 (82%) low-risk men undergoing RP (p<0.001). Overall, the low-risk AS population had fewer positive biopsy cores (median 1 vs. 3, p<0.001) and lower maximum percentage core involvement (median 10% vs. 40%, p<0.001) compared to low-risk RP patients.

Data supporting safety of AS in low-risk men at our institution are derived from a distinct subgroup harboring limited cancer volume. Until acceptable outcomes are confirmed in higher-volume tumors, it is important to remain mindful of these limitations before broadly recommending AS to all low-risk men.

The Journal of urology. 2017 Oct 23 [Epub ahead of print]

Jeffrey J Tosoian, Mufaddal Mamawala, Hiten D Patel, Ridwan Alam, Jonathan I Epstein, Ashley E Ross, H Ballentine Carter

The James Buchanan Brady Urological Institute, Department of Urology. Electronic address: ., The James Buchanan Brady Urological Institute, Department of Urology., Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.